
Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …
Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …
European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

